Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

NCT05704985 is registered in ClinicalTrials.gov with DEKA Biosciences as lead sponsor.

NCT NCT05704985
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05704985 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy
Lead sponsor
DEKA Biosciences
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 3, 2023
Completion date
October 31, 2025
Enrollment
39 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, colorectal cancer, gynecologic cancer, head and neck cancer, kidney cancer, non small cell lung cancer, pancreas cancer, skin cancer, solid tumor